Fate Therapeutics, Memorial Sloan Kettering deal

Fate Therapeutics partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to develop off-the-shelf T cell immunotherapies derived from engineered pluripotent cell lines. Under the three-year deal, Fate said the partners will seek to create pluripotent cell lines that are engineered for “enhanced antigen specificity and functionality” and work to optimize T cell differentiation protocols. Fate said the partnership will combine its experience in pluripotent cell generation, engineering and differentiation with MSKCC’s cell-based immunotherapy manufacturing and delivery expertise. ...